Gene therapy, gene therapy, biotechnology, biotechnology, biomanufacturing, enzymatic, synthetic, enzymatic, synthetic, DNA, DNA, synthetic DNA, enzymatic DNA, alternative to plasmid, AAV, rAAV, adeno-associated viruses, partner, CDMO, AAV manufacturing.
TAAV Biomanufacturing Solutions, SLU (TAAV), a wholly owned subsidiary of Asklepios Biopharmaceuticals (AskBio) and Bayer AG, manufactures enzymatic DNA for the production of recombinant adeno-associated viruses (rAAVs) used in gene therapies.
This synthetic material, called neDNA™, is manufactured in a biotechnological process following Good Manufacturing Practice (GMP) for clinical and commercial applications of DNA in rAAV therapeutic vectors.
neDNA™ is an alternative to the plasmid DNA commonly used in the manufacture of rAAVs. Its use can significantly shorten manufacturing lead times and facilitate faster production of rAAVs with a higher safety profile by eliminating residual bacterial sequences of plasmid DNA in the rAAV product.
TAAV was founded in 2019 and became 100% owned by AskBio in 2022. The company’s headquarters, manufacturing facilities and laboratories are located in San Sebastian, Spain.
DESCRIPTION:
TAAV Biomanufacturing Solutions, SLU (TAAV), a wholly owned subsidiary of Asklepios Biopharmaceuticals (AskBio) and Bayer AG, manufactures enzymatic DNA for the production of recombinant adeno-associated viruses (rAAVs) used in gene therapies.
This synthetic material, called neDNA™, is manufactured in a biotechnological process following Good Manufacturing Practice (GMP) for clinical and commercial applications of DNA in rAAV therapeutic vectors.
neDNA™ is an alternative to the plasmid DNA commonly used in the manufacture of rAAVs. Its use can significantly shorten manufacturing lead times and facilitate faster production of rAAVs with a higher safety profile by eliminating residual bacterial sequences of plasmid DNA in the rAAV product.
TAAV was founded in 2019 and became 100% owned by AskBio in 2022. The company’s headquarters, manufacturing facilities and laboratories are located in San Sebastian, Spain.
Key words:
Gene therapy, gene therapy, biotechnology, biotechnology, biomanufacturing, enzymatic, synthetic, enzymatic, synthetic, DNA, DNA, synthetic DNA, enzymatic DNA, alternative to plasmid, AAV, rAAV, adeno-associated viruses, partner, CDMO, AAV manufacturing,
